The TRANSCEND-T2D Program: A Separate Diabetes-Specific Track Distinct from TRIUMPH, Eli Lilly runs TRANSCEND-T2D a dedicated, multi-trial Phase 3 program focused specifically on type 2 diabetes, having enrolled more than 2,050 participants since 2024
10.1016/j.idh.2017.07.001 Inf
Different plant origins of pollen grains contain all essential amino acids in fewer amount (89, 182)
Some receptor pathways have multiple receptor subtypes or isoforms that produce the same downstream effect (Baker and Hill 2007), further increasing the likelihood that CBD could chemically interact with the pathway
Schlumberger M, Pacini F, Wiersinga WM, Toft A, Smit JW, Sanchez Franco F, Lind P, Limbert E, Jarzab B, Jamar F, Duntas L, Cohen O, Berg G
Phase 2 clinical trial data published in the New England Journal of Medicine (Jastreboff et al., 2023) reported potentially significant effects on body weight reduction and glycaemic control